The usefulness of the total metabolic tumor volume for predicting the postoperative recurrence of thoracic esophageal squamous cell carcinoma

Hayato Kaida1,2*, Takushi Yasuda3, Osamu Shiraishi3, Hiroaki Kato3, Yutaka Kimura3, Kohei Hanaoka2, Minoru Yamada1,2, Yuko Matsukubo1,2, Masakatsu Tsurusaki1, Kazuhiro Kitajima4, Satoshi Hattori5,6 and Kazunari Ishii1,2

Abstract

Background: Induction or adjuvant therapies are not always beneficial for thoracic esophageal squamous cell carcinoma (ESCC) patients, and it is thus important to identify patients at high risk for postoperative ESCC recurrence. We investigated the usefulness of the total metabolic tumor volume (TMTV) for predicting the postoperative recurrence of thoracic ESCC.

Methods: We retrospectively analyzed the cases of 163 thoracic ESCC patients (135 men, 28 women; median age of 66 [range 34–82] years) treated at our hospital in 2007–2012. The TMTV was calculated from the fluorine-18 fluorodeoxyglucose (18F-FDG) uptake in the primary lesion and lymph node metastases. The optimal cut-off values for relapse and non-relapse were obtained by the time-dependent receiver operating curve analyses. Relapse-free survival (RFS) was evaluated by the Kaplan-Meier method, and between-subgroup differences in survival were analyzed by log-rank test. The prognostic significance of metabolic parameters and clinicopathological variables was assessed by a Cox proportional hazard regression analysis. The difference in the failure patterns after surgical resection was evaluated using the χ2-test.

Results: The optimal cut-off value of TMTV for discriminating relapse from non-relapse was 3.82. The patients with a TMTV ≥3.82 showed significantly worse prognoses than those with low values (p < 0.001). The TMTV was significantly related to RFS (model 1 for preoperative risk factors: TMTV: hazard ratio [HR] = 2.574, p = 0.004; model 2 for preoperative and postoperative risk factors: HR = 1.989, p = 0.044). The combination of the TMTV and cN0–1 or pN0–1 stage significantly stratified the patients into low- and high-risk recurrence groups (TMTV cN0–1, p < 0.001; TMTV pN0–1, p = 0.004). The rates of hematogenous and regional lymph node metastasis were significantly higher in the patients with TMTV ≥3.82 than those with low values (hematogenous metastasis, p < 0.001, regional lymph node metastasis, p = 0.011).

*Correspondence: kaida@med.kindai.ac.jp

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: The TMTV was a more significantly independent prognostic factor for RFS than any other PET parameter in patients with resectable thoracic ESCC. The TMTV may be useful for the identifying thoracic ESCC patients at high risk for postoperative recurrence and for deciding the patient management.

Keywords: Esophageal squamous cell carcinoma, \(^{18}\)F-FDG-PET/CT, TMTV

Background

Esophageal cancer ranks seventh in terms of incidence and sixth in mortality in the world, and it has shown high rates of recurrence and distant metastasis in patients with pathological lymph node metastases (LNMs) [1, 2]. In western countries, neoadjuvant chemoradiotherapy (NACRT) plus surgery is considered the standard treatment for patients with resectable locally advanced esophageal cancer [3]. In Japan, neoadjuvant chemotherapy (NAC) is another standard therapy for patients with stage II/III esophageal squamous cell carcinoma (ESCC) [4]. Unfortunately, these induction therapies are not always beneficial for all patients. It is therefore crucial to identify patients who are at high risk for recurrence, at the initial staging. The tumor-node metastasis (TNM) stage is currently the most valued factor for deciding patient management and predicting patient survival, but this system does not include biological information, and many patients even at the early stage of esophageal cancer show early recurrence and metastasis. A more selective biomarker for predicting ESCC recurrence and metastasis is needed.

The maximum standardized uptake value (SUVmax) is a commonly used semi-quantitative parameter used to evaluate malignant tumors on fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (\(^{18}\)F-FDG-PET/CT). Although this parameter reflects the highest pixels within a designated region of interest, it does not always reveal the glucose metabolism within the whole tumor. Total lesion glycolysis (TLG) and the metabolic tumor volume (MTV) are representative PET volumetric parameters. The MTV is an important parameter to determine the local tumor burden and the total tumor burden obtained by a commonly fixed threshold method, and it is usually expressed in milliliters or cubic centimeters [5]. The TLG value provides information about total tumor glycolysis calculated from the following formula: SUVmean × MTV [5]. In other words, the TLG takes into account the intensity of radiotracer uptake and a volumetric factor [5].

For patients with esophageal cancer, a change in the MTV of the primary tumor was recently reported to be clinically useful in predicting both long-term survival and histological response to NAC, and the MTV of the primary tumor has been suggested to be a significant prognostic factor in patients treated with chemoradiotherapy (CRT) [6, 7]. Thus, the relationship between the \(^{18}\)F-FDG uptake in the primary tumor and the patients’ survival has been investigated. However, the number of pathological LNMs is a crucial factor for postoperative survival, and the preoperative \(^{18}\)F-FDG uptake in lymph nodes status has been suggested to be significantly associated with the size and the number of pathological LNMs and survival in patients with resectable ESCC [8]. It is critically important to determine the correlation between prognosis and the \(^{18}\)F-FDG uptake in both the primary tumor and LNMs.

The measurement of the total metabolic tumor volume (TMTV, which gives an estimation of the total tumor burden) has gained attention, and the usefulness of the TMTV for predicting tumor responses and prognoses has been reported in several malignant tumors [9, 10]. The TMTV and whole-body TLG (wTLG) have been reported to be independent prognostic factors in esophageal cancer patients treated with CRT [11]. To our knowledge, there have been few investigations about the relationship between recurrence and TMTV in ESCC patients undergoing curative surgical resection. We conducted the present study to investigate the usefulness of the TMTV compared with other PET parameters (i.e., the SUVmax, lean body mass SUVpeak [SULpeak], and TLG) for predicting postoperative recurrence in thoracic ESCC patients.

Patients and methods

Patients

The eligibility of patient for this study is all of the included thoracic ESCC patients who underwent a complete curative surgical resection without prior induction treatment during the period from December 2007 to December 2012. Our inclusion criteria are demonstrated in Fig. 1. On treatment strategy of thoracic ESCC patients in our institution, the patients with cStage I underwent curative surgical resection without NAC. In patients with cStage II, III, IV (M1LYM), NAC followed by radical surgical resection was considered as first line therapy, and whether these patients were candidate for NAC was determined considering \(^{18}\)F-FDG PET/CT result. The eligibility of NAC is following criteria; cT3 or less, resectable, and histologically confirmed thoracic ESCC, with presence of PET-N-positive \(^{18}\)F-FDG uptake on PET observed in lymph nodes within a three-field
region, including M1LYM of the suprACLavicular, cerviClAL paratracheAL and celiac artery lymph nodes), no evidence distant metastasis, age 20–79 years, Eastern Cooperative Oncology Group performance status 0–1, adequate hematological and visceral function, no severe diabetes mellitus, no severe mental disorder, no previous chemo-or radiotherapy for any malignancies, and no active malignant disease [12]. In case of PET-N-negative patients, curative surgical resection without NAC was done. Unfortunately, provided that intramural metastasis was present, or lymph node metastasis was suspected from CT of the neck, chest and abdomen in spite of PET-N-negative, NAC was also conducted to thoracic ESCC patients who met these conditions. The final study population was 163 patients (135 men, 28 women) with the median age of 66 (range 34–82) years. The TNM stages were established using the seventh edition of the UICC for staging esophageal cancer [13]. The study protocol was conducted according to the Declaration of Helsinki and was approved by the Ethics Committee, Kindai University Faculty of Medicine (approval no. 28–005), which waived the need for written informed consent due to the study’s retrospective design.

**18F-FDG-PET/CT imaging acquisition**

An integrated PET/CT scanner (Biograph/Somatom Emotion Duo, Siemens Medical Solutions, Hoffmann Estates, IL, USA) was used for the data acquisition. All PET images were acquired using a matrix of 128 × 128 pixels. The time needed for one bed position (162 mm in the z-direction) scan was 120–150 sec. The voxel dimensions were 3.9 mm × 3.9 mm × 5.0 mm.

The CT data were used for attenuation correction and lesion localization. After both the CT and emission images were transmitted, the images were reconstructed using the standard normal reconstruction protocol based on the ordered subset expectation maximization method and a 5-mm Gaussian filter. Before receiving the 18F-FDG injection, the patient fasted for 4 hr. We included six patients with diabetes mellitus because hyperglycemia
with a pre-scan blood glucose level at 110–200 mg/dL is not associated with significantly different SUVmax and SUVmean values in the tumor [14]. None of the patients had a glucose level > 200 mg/dL. All patients were administered a median dose of 156.3 MBq (adjusted for body weight, range 87–243 MBq) via the antecubital vein, and they were then instructed to rest quietly for approx. 60 min. The median duration between the surgical resection and 18F-FDG-PET/CT was 23 days (range 1–56 days).

18F-FDG-PET/CT image analysis
18F-FDG-PET/CT images were displayed on an Advantage Windows Workstation (GE Healthcare, Milwaukee, WI) on which volumes of interest (VOIs) were semi-automatically drawn over the entire abnormal uptake of the primary tumor and any lymph node metastasis on axial images. The SUVmax and the SUVmean were defined as the maximum and mean activity, respectively, of the concentration of 18F-FDG uptake in the primary tumor or lymph node metastasis. We used 40% as the threshold of the maximum peak activity within the lesions to delineate the MTV [15].

The SUVpeak was calculated in a 1.2-cm-dia. Region of interest (ROI) placed on the uptake lesions and defined as the average SUV inside an ROI centered in the highest uptake volume of the lesion [5]. The SUVpeak was normalized to the SULpeak as follows: SUVpeak × [lean body mass] / [total body mass]. Lean body mass was calculated based on a published formula [16]. The border of the VOI was adjusted manually by avoiding overlap with the adjacent 18F-FDG-avid structures, physiological uptake, and lesions. The SUVmax, MTV, TLG, and SULpeak of each lesion were automatically calculated and recorded on the workstation.

For the evaluations of LNMs, we considered paraeosophageal or other mediastinal and abdominal lymph nodes with 18F-FDG uptake that was higher than the mediastinal blood pool activity on visual inspection as metastasis, and we assessed PET-N-positive and PET-N-negative based on 18F-FDG PET/CT finding and the respective patient’s postoperative histopathological findings. The highest SUVmax (peakSUVmax) and the highest SULpeak (hSULpeak) were selected from the 18F-FDG uptake in the primary tumor and LNMs, respectively. The TMTV and the wTLG were calculated by summing the TLG (or MTV) of the primary tumor and the TLG (or MTV) of all LNMs (Suppl. Fig.S1).

Surgical treatment and follow-up
All patients underwent a transthoracic subtotal esophagectomy, and an esophageal reconstruction was done using a gastric tube (149 patients) or a pedicle jejunum (14 patients due to simultaneous total gastrectomy or history of distal gastrectomy). A three-field lymphadenectomy was performed for patients with supraclavicular or recurrent laryngeal nerve LNMs or with a primary tumor located in the upper-third thoracic esophagus. The surviving patients were followed up at our outpatient department every 3–6 months for the first 5 years, and then on an annual basis. CT scans of the neck, chest, and abdomen were conducted 2 × /year, and endoscopy was performed 1 × /year.

Statistical analyses
Relapse-free survival (RFS) was defined as the length of time from the date of the patient’s surgery until the date of the first evidence of relapse or the date of death from any cause. As the event occurrence is time-dependent, we performed a time-dependent receiver operating characteristics curve (ROC) analysis for censored survival data and relapse and used the area under the ROC curve (AUC) as the criterion [17, 18]. A larger AUC indicates better predictability of the time to an event. An AUC of 0.5 indicates no predictive ability, and a value of 1 represents perfect ability [17]. The optimal cut-off values for PET/CT parameters for the patients’ RFS were determined by a time-dependent ROC analysis. We used the χ²-test to evaluate the differences in the noncontinuous data between all metabolic parameters and various clinicopathological variables or failure patterns after surgical resection.

We used univariate and multivariable Cox proportional hazard models to evaluate the effects of metabolic parameters on the patients’ RFS. However, due to the high collinearity among all PET parameters (Spearman correlation test; r = 0.82–0.99), we performed two models of multivariate analysis using the PET parameters one-by-one. Model 1 consisted of preoperative risk factors such as age, gender, location, and clinical TNM stage. Model 2 was composed of both preoperative risk factors and the pathological TNM stage. Significant univariate variables (p < 0.05) were included in the multivariate analysis.

Using the cut-off values, we estimated the survival functions of RFS for the low- and high-risk groups by the Kaplan-Meier method, and we compared these functions by the log-rank test. Differences at p < 0.05 were regarded as significant. Statistical analyses were conducted using SPSS Statistics 27 software (IBM, Armonk, NY), and R v3.4.1; downloadable at https://cran.r-project.org/bin/windows/base/old/3.4.1/.

Results
Time-dependent ROC analysis for RFS
We conducted a time-dependent ROC analysis to compare the PET parameters for predicting recurrence, and
the results provided the AUC for each follow-up time. The resultant AUC data for the patients’ RFS are depicted in Fig. 2. The best accuracy for predicting recurrence until 72 months was obtained with TMTV (AUC: 0.786–0.85), wTLG (AUC: 0.732–0.821), hSULpeak (AUC: 0.713–0.787), and peakSUVmax (AUC: 0.706–0.777). The optimal cut-off values for relapse and non-relapse until 72 months were as follows. PeakSUVmax: 4.43, hSULpeak: 2.64, TMTV: 3.82, wTLG: 13.46.

Patient characteristics and metabolic parameters
The patients’ characteristics and clinicopathological variables are summarized in Table 1. Sixty-three of the 163 patients did not receive NAC despite being at cStage II, III, or IV, and twenty-six of the 63 patients who were PET-N-negative did not undergo NAC because PET-N-negative ESCC patients have been reported to be at significantly lower risk for postoperative recurrence and to have a higher survival rate without NAC [8]. The PET-N-positive patients with resectable tumors clinically considered candidates for NAC, and this therapy was performed to these patients because they are likely to have higher rate of postoperative recurrence and distant metastasis, and NAC significantly suppressed postoperative recurrence in thoracic ESCC patients [8, 12]. Twelve patients with PET-N-negative and twenty-five patients with PET-N-positive were considered as candidate for NAC, unfortunately this therapy was not performed based on several medical reasons (Table S1). Regarding PET-N-positive, seven patients underwent curative surgical resection without NAC as local disease because of lymph node metastasis adjacent to primary tumor.

The clinical and pathological advanced stages (except for the cM stage or pM stage), the number of 18F-FDG-positive lymph node metastases, and the rate of recurrence were significantly different between the high cut-off value groups and the low cut-off value groups for all four metabolic parameters (p < 0.001 for all). Patient age, gender, and tumor location were not significantly

| Time | peakSUVmax | TMTV | wTLG | hSULpeak |
|------|------------|------|------|----------|
| 3    | 0.63       | 0.756| 0.713| 0.661    |
| 6    | 0.712      | 0.787| 0.767| 0.715    |
| 9    | 0.755      | 0.812| 0.794| 0.766    |
| 12   | 0.777      | 0.86 | 0.821| 0.787    |
| 24   | 0.762      | 0.817| 0.794| 0.772    |
| 36   | 0.748      | 0.779| 0.764| 0.754    |
| 48   | 0.706      | 0.754| 0.732| 0.713    |
| 60   | 0.731      | 0.786| 0.764| 0.743    |
| 72   | 0.731      | 0.786| 0.764| 0.743    |

Fig. 2 a The results of the time-dependent ROC curve analysis for the prediction of RFS regarding all PET parameters b–e The time-dependent ROC curve analysis for the determination of cut-off values of four PET parameters for predicting 72 months RFS. AUC: the area under the curve, hSULpeak: highest lean body mass peak standardized uptake value, peakSUVmax: peak maximum standardized uptake value, PET: positron emission tomography, RFS: relapse-free survival, ROC: receiver operating characteristics curve, TMTV: total metabolic tumor volume, wTLG: whole-body total lesion glycolysis
associated with any of the metabolic parameters. These data are shown in Supplementary Tables S2 and S3.

The relationships between the PET parameters and survival

The median follow-up period of all patients was 60 months (range 3–72 months). Fifty-one of the 163 patients (31.1%) developed recurrence, and 60 (36.6%) patients died. The 5-year RFS rate for this patient population was 57.9%. The results of the log-rank tests of the Kaplan-Meier survival curves for 5-year RFS regarding all PET parameters and clinicopathological variables are shown in Table 2. Regarding the 5-year RFS, the survival of the patients with all low values on the four metabolic parameters of peakSUVmax, hSULpeak, TMTV, and wTLG were significantly longer than those of the high-value groups (p < 0.001 for all). There were also significant differences in the RFS in relation to the cTstage, cN stage, and pTNM stage. The results of the univariate Cox proportional hazard models for RFS are provided in Table 3. The univariate analysis showed significant correlations between RFS and the cTstage, cN stage, peakSUVmax, TMTV, wTLG, hSULpeak, pT stage, pN stage, and pM stage. In the

### Table 1  The characteristic of the thoracic ESCC patients (n= 163)

| Age, yrs. (median) | 66 (range 34–82) |
|-------------------|------------------|
| Gender, males/females | 135/28 |
| Location: upper/middle/lower | 25/97/41 |
| Clinical stage: | |
| cT1/cT2/cT3 | 87/40/36 |
| cN0/cN1/cN2 | 113/42/8 |
| cM0/cM1(LYM) | 162/1 |
| cStage (I/II/III/IV) | 100/35/27/1 |
| Pathological stage: | |
| pT1/pT2/pT3/pT4 | 93/21/47/2 |
| pN0/pN1/pN2/pN3 | 88/45/22/8 |
| pM0/pM1(LYM) | 159/4 |
| pStage, I/II/III/IV | 75/41/37/10 |
| Postoperative therapy: | |
| Absent/present | 127/36 |
| Chemotherapy | 24 |
| Chemotherapy and cancer-specific vaccine therapy | 5 |
| Cancer-specific vaccine therapy | 5 |
| CRT | 2 |
| Median follow-up duration, months (range) | 60.0 (3–72) |
| Recurrence, negative/positive | 112/51 |
| Censored patients/death | 104/59 |

CRT Chemoradiotherapy, LYM Supraclavicular lymph node metastasis, ESCC Esophageal squamous cell carcinoma

### Table 2  Log-rank test of PET parameters and clinicopathological factors for relapse-free survival (RFS)

| Parameters | n | 5-yr survival rate | p-value |
|------------|---|-------------------|---------|
| Age:       |   |                   |         |
| < 66       | 78 | 59.9%             | 0.514   |
| ≥ 66       | 85 | 55.6%             |         |
| Gender:    |   |                   |         |
| Male       | 135 | 58.8%             | 0.373   |
| Female     | 28  | 51.8%             |         |
| Location:  |   |                   |         |
| Ut-Mt      | 121 | 58.0%             | 0.878   |
| Lt         | 42  | 56.6%             | 0.134   |
| Mt-Lt      | 138 | 59.6%             |         |
| Ut         | 25  | 47.7%             |         |
| cT stage:  |   |                   |         |
| cT1–2      | 128 | 66.0%             | <0.001  |
| cT3        | 35  | 27.1%             |         |
| cN stage:  |   |                   |         |
| cN0        | 113 | 68.3%             | <0.001  |
| cN1–2      | 50  | 32.8%             |         |
| cM stage:  |   |                   |         |
| cM0        | 162 | 58.0%             | 0.165   |
| cM1(LYM)   | 1   | NA                |         |
| pT stage:  |   |                   |         |
| pT1–2      | 114 | 69.8%             | <0.001  |
| pT3–4      | 49  | 28.2%             |         |
| pN stage:  |   |                   |         |
| pN0–1      | 133 | 67.4%             | <0.001  |
| pN2–3      | 30  | 14.0%             |         |
| pM stage:  |   |                   |         |
| pM0        | 159 | 58.5%             | 0.035   |
| pM1(LYM)   | 4   | NA                |         |
| peakSUVmax:|   |                   |         |
| < 4.43     | 71  | 74.9%             | <0.001  |
| ≥ 4.43     | 92  | 44.1%             |         |
| TMTV:      |   |                   |         |
| < 3.82     | 76  | 77.9%             | <0.001  |
| ≥ 3.82     | 87  | 39.7%             |         |
| wTLG:      |   |                   |         |
| < 13.46    | 78  | 73.1%             | <0.001  |
| ≥ 13.46    | 85  | 43.2%             |         |
| hSULpeak:  |   |                   |         |
| < 2.64     | 68  | 75.2%             | <0.001  |
| ≥ 2.64     | 95  | 44.8%             |         |

peakSUVmax: Highest lean body mass peak standardized uptake value, Lt Lower thoracic esophagus, Mt Middle thoracic esophagus, LYM Supraclavicular lymph node metastasis, PeakSUVmax Peak maximum standardized uptake value, PET Positron emission tomography, TMTV Total metabolic tumor volume, Ut Upper thoracic esophagus, wTLG Whole-body total lesion glycolysis
multivariable analysis for both models, TMTV remained significantly correlated with RFS (model 1: hazard ratio [HR] = 2.574, 95% confidential interval [95%CI] 1.338–4.826, p = 0.004; model 2: HR = 1.989, 95%CI 1.018–3.885, p = 0.044). Unfortunately, other PET parameters were not significantly associated with RFS for both models (Tables 4 and 5).

Based on the result of the multivariate analysis, we investigated the Kaplan-Meier survival curves for the RFS related to the combination of the TMTV and cN stage or pN stage. The 5-year RFS rate of the 155 patients with cN0 and cN1 disease was 58.2%; the 5-year RFS rate of the patients with cN0 was 68.3%, and that of the patients with cN1 was 30.0% (p < 0.001). The combination of TMTV and cN0–1 stage was significantly associated with RFS (p < 0.001). For TMTV and cN stage, the 5-year RFS rate of the patients with TMTV < 3.82 cN0–1, TMTV ≥ 3.82 cN0, and TMTV ≥ 3.82 cN1 were 77.6, 53.9, and 23.3%, respectively (Fig. 3). The characteristics of these subgroups are shown in Table 6.

The number of patients with cStage I in the TMTV < 3.82 cN0–1 group was higher than those of all of the other groups, and that of the patients with cStage II/III was higher in the TMTV ≥ 3.82 cN1 group was higher than those of the other two groups. However, the TMTV ≥ 3.82 cN0 group had 30 patients (71.4%) with cStage I. Regarding these analyses, we did not separate the patients with TMTV < 3.8 into cN0 and cN1 because the number of patients with TMTV < 3.82 cN1 was only four patients who had no recurrent lesions or died within 72 months of follow-up.

For the subgroup of 133 patients with pN0 and pN1 disease, the 5-year RFS rate of all patients was 67.4%, and the 5-year RFS rates of the patients with pN0 and those with pN1 were 72.2 and 57.3%, respectively (p = 0.041). The combination of the TMTV and pN0–1 stage significantly stratified high-risk patients by RFS (p = 0.004) in the following order: TMTV < 3.82 pN0 (5-yr RFS, 81.8%), TMTV < 3.82 pN1 (66.5%), TMTV ≥ 3.82 pN0 (53.6%), and TMTV ≥ 3.82 pN1 (52.9%) (Fig. 4). The characteristics of the TMTV and pN0–1 group are summarized in Table 7. The TMTV < 3.82 pN0 group included more thoracic ESCC patients with cStage I and pStage I than all of the other groups. The TMTV ≥ 3.82 pN0 group and the TMTV ≥ 3.82 pN1 group had more cStage II or III patients than the other two groups, and the TMTV ≥ 3.82 pN1 group had more pStage II–IV patients than all of the other groups.

On the other hand, the TMTV ≥ 3.82 pN0 group had 20 patients (67.7%) with cStage I and 18 patients (58.1%) with pStage I, and the TMTV ≥ 3.82 pN1 group had nine patients (32.1%) with cStage I. The numbers of patients with pN0 and pN1 undergoing postoperative adjuvant chemotherapy were as follows; TMTV < 3.82 pN0: 0% (0/58), TMTV < 3.82 pN1: 35.3% (5/16), TMTV ≥ 3.82 pN0: 67.7% (13/19), and TMTV ≥ 3.82 pN1: 58.1% (10/17).

### Table 3

| Univariate Cox regression analysis for relapse-free survival (RFS) | HR (95%CI) | p-value |
|---|---|---|
| Gender, male/female | 0.761 (0.416–1.393) | 0.377 |
| Age, <66/ ≥66 | 1.171 (0.726–1.887) | 0.517 |
| Tumor location: | | |
| UlMt/Lt | 1.076 (0.628–1.845) | 0.789 |
| Ul/MtLt | 0.648 (0.360–1.167) | 0.148 |
| Clinical stage: | | |
| cT stage, T1–2/T3 | 3.543 (2.151–5.838) | <0.001 |
| cN stage, N0/N1–2 | 0.301 (0.185–0.488) | <0.001 |
| cM stage, M0/M1(LYM) | 0.274 (0.038–1.998) | 0.202 |
| PET parameters: | | |
| peakSUVmax, <4.43/ ≥4.43 | 3.346 (1.929–5.805) | <0.001 |
| hSULpeak, <2.64/ ≥2.64 | 3.325 (1.896–5.834) | <0.001 |
| TMTV, <3.82/ ≥3.82 | 4.019 (2.313–6.982) | <0.001 |
| wTLG, <13.46/ ≥13.46 | 2.996 (1.786–5.024) | <0.001 |
| Pathological stage: | | |
| pT stage, T1–2/T3–4 | 0.262 (0.162–0.423) | <0.001 |
| pN stage, N0–1/N2–3 | 0.211 (0.127–0.350) | <0.001 |
| pM stage, M0/M1(LYM) | 0.308 (0.096–0.987) | 0.048 |

Abbreviations are explained in the earlier table footnotes

### Table 4

| Model 1 for the multivariate Cox regression analysis for RFS | peakSUVmax HR (95%CI) | p-value | hSULpeak HR (95%CI) | p-value | TMTV HR (95%CI) | p-value | wTLG HR (95%CI) | p-value |
|---|---|---|---|---|---|---|---|---|
| cT stage, T1–2/T3 | 1.980 (1.126–3.480) | 0.018 | 1.995 (1.137–3.499) | 0.016 | 1.733 (0.987–3.403) | 0.056 | 2.081 (1.167–3.771) | 0.013 |
| cN stage, N0/N1–2 | 0.522 (0.297–0.914) | 0.023 | 0.515 (0.295–0.900) | 0.020 | 0.544 (0.316–0.939) | 0.029 | 0.498 (0.277–0.897) | 0.020 |
| cM stage, M0/M1(LYM) | 0.197 (0.043–4.43) | 0.056 | 1.907 (0.984–3.699) | 0.056 | 1.916 (0.987–3.719) | 0.055 | 2.574 (1.338–4.826) | 0.004 |
| peakSUVmax, <4.43/ ≥4.43 | 1.907 (0.984–3.699) | 0.056 | 1.916 (0.987–3.719) | 0.055 | 2.574 (1.338–4.826) | 0.004 | 1.560 (0.802–3.037) | 0.19 |
| hSULpeak, <2.64/ ≥2.64 | 1.916 (0.987–3.719) | 0.055 | 2.574 (1.338–4.826) | 0.004 | 1.560 (0.802–3.037) | 0.19 | | |
| TMTV, <3.82/ ≥3.82 | 4.019 (2.313–6.982) | <0.001 | 2.996 (1.786–5.024) | <0.001 | 1.733 (0.987–3.403) | 0.056 | 2.081 (1.167–3.771) | 0.013 |
| wTLG, <13.46/ ≥13.46 | 2.996 (1.786–5.024) | <0.001 | 1.733 (0.987–3.403) | 0.056 | 2.081 (1.167–3.771) | 0.013 | 1.560 (0.802–3.037) | 0.19 |
In addition, we investigated the relationship between the patient group about surgical resection alone (SA) and that about surgical resection without NAC due to several medical reasons (SMR) to RFS. The patients with SA were significantly lower-risk group for recurrence than those with SMR, and the 5-year RFS rates of the group of SA and that of SMR were 66.0 and 27.7% respectively (*p* < 0.001) (Fig. 5a). The combination of the TMTV and these groups significantly stratified high-risk for recurrence as following order: TMTV < 3.82 SA and SMR (5-yr RFS, 77.9%), TMTV ≥ 3.82 SA (50.0%), and TMTV ≥ 3.82 SMR (20.4%) respectively (Fig. 5b), and the characteristics of these groups are shown in Table 8. The patients with TMTV < 3.82

### Table 5

Model 2 for the multivariate Cox regression analysis for RFS

| Abbreviations | peakSUVmax (HR (95%CI)) | p-value | hSULpeak (HR (95%CI)) | p-value | TMTV (HR (95%CI)) | p-value | wTLG (HR (95%CI)) | p-value |
|---------------|-------------------------|---------|------------------------|---------|-------------------|---------|-------------------|---------|
| cT stage, T1–2/T3 | 1.355 (0.688–2.670) | 0.337 | 1.354 (0.687–2.667) | 0.381 | 1.214 (0.616–2.392) | 0.530 | 1.377 (0.693–2.737) | 0.362 |
| cN stage, N0/N1–2 | 0.762 (0.410–1.414) | 0.762 | 0.764 (0.413–1.411) | 0.390 | 0.765 (0.426–1.375) | 0.371 | 0.696 (0.368–1.318) | 0.266 |
| cM stage, M0/M1 (LYM) | | | | | | | | |
| peakSUVmax, <4.43 / ≥ 4.43 | 1.501 (0.718–3.139) | 0.280 | | | | | | |
| hSULpeak, <2.64 / ≥ 2.64 | 1.543 (0.743–3.203) | 0.245 | | | | | | |
| TMTV, <3.82 / ≥ 3.82 | 1.989 (1.018–3.885) | 0.044 | | | | | | |
| wTLG, <13.46 / ≥ 13.46 | 1.115 (0.518–2.400) | 0.781 | | | | | | |
| pT stage, T1–2/T3–4 | 0.535 (0.263–1.088) | 0.084 | 0.537 (0.266–1.084) | 0.083 | 0.524 (0.271–1.013) | 0.055 | 0.477 (0.225–1.012) | 0.054 |
| pN stage, N0–1/N2-3 | 0.352 (0.195–0.636) | 0.001 | 0.351 (0.193–0.630) | 0.001 | 0.401 (0.220–0.730) | 0.003 | 0.356 (0.198–0.640) | 0.001 |
| pM stage, M0/M1 (LYM) | 0.637 (0.194–2.091) | 0.457 | 0.638 (0.194–2.094) | 0.458 | 0.542 (0.165–1.781) | 0.313 | 0.604 (0.184–1.980) | 0.405 |

Abbreviations are explained in the earlier table footnotes

### Table 6

The characteristics of the thoracic ESCC patients with combined TMTV and cN0–1

| TMTV < 3.82 | TMTV ≥ 3.82 | TMTV ≥ 3.82 |
|-------------|-------------|-------------|
| cN0–1       | cN0         | cN1         |
| Total patients | 75          | 42          | 38          |
| Age, <66 / ≥ 66 | 37 / 38    | 22 / 20    | 15 / 10     |
| Gender, males/females | 66 / 9     | 34 / 8     | 29 / 7      |
| Location: upper/mid/middle/ lower | 11 / 48 / 16 | 5 / 25 / 12 | 7 / 19 / 12 |
| Clinical stage: | | | |
| cT1 / cT2 / cT3 | 67 / 7 / 1  | 15 / 15 / 12 | 4 / 15 / 19 |
| cM0 / cM1 / LYM | 75 / 0     | 42 / 0     | 38 / 0      |
| cStage, I / II / III / IV | 70 / 5 / 0 / 0 | 30 / 11 / 0 / 0 | 0 / 19 / 19 / 0 |
| Recurrence, negative / positive | 69 / 6 | 26 / 16 | 13 / 25 |

ESCC Esophageal squamous cell carcinoma, TMTV Total metabolic tumor volume, LYM Supraclavicular lymph node metastasis

TMTV ≥ 3.82 pN0 0% (0/31), and TMTV ≥ 3.82 pN1: 46.4% (13/28).

In addition, we investigated the relationship between the patient group about surgical resection alone (SA) and that about surgical resection without NAC due to several medical reasons (SMR) to RFS. The patients with SA were significantly lower-risk group for recurrence than those with SMR, and the 5-year RFS rates of the group of SA and that of SMR were 66.0 and 27.7% respectively (*p* < 0.001) (Fig. 5a). The combination of the TMTV and these groups significantly stratified high-risk for recurrence as following order: TMTV < 3.82 SA and SMR (5-yr RFS, 77.9%), TMTV ≥ 3.82 SA (50.0%), and TMTV ≥ 3.82 SMR (20.4%) respectively (Fig. 5b), and the characteristics of these groups are shown in Table 8. The patients with TMTV < 3.82...
include both SA and SMR groups because the number of patients with TMTV < 3.82 SMR was only six, and these patients had no recurrence and death during follow-up period. This group had 70 patients (92.1%) with cStage I, 57 patients (75.0%) with pStage I, and a few patients with PET-N-positive and pathological LNMs ≥3. Another two groups had more patients with pathological LNMs ≥3 and with advanced pStage III-IV than those with TMTV < 3.82 SA and SMR. TMTV ≥3.82 SMR group had the highest number of PET-N-positive and pathological LNMs ≥3 patients than any other group.

**The failure patterns after surgical resection according to TMTV**

We compared the failure patterns based on the cut-off value of TMTV for all patients (Table 9). The total recurrence and metastasis rates were both significantly lower in the patients with a TMTV <3.82 compared to the patients with a TMTV ≥3.82, as follows: TMTV <3.82, 7.9% (6/76); TMTV ≥3.82, 51.7% (45/87), p < 0.001.

![Fig. 4](image-url)  
**Fig. 4** Kaplan-Meier estimates of survival functions for RFS in the pN0–1 group (a) and the combination of TMTV < 3.8 pN0, TMTV < 3.8 pN1, TMTV ≥3.8 pN0, and TMTV ≥3.8 pN1 groups in 133 thoracic ESCC patients (b). P-values were determined by the log-rank test

| TMTV < 3.82 pN0 | TMTV < 3.82 pN1 | TMTV ≥3.8 pN0 | TMTV ≥3.8 pN1 |
|------------------|------------------|---------------|---------------|
| Total patients   | 58               | 16            | 31            | 28            |
| Age, <66/≥66     | 27/31            | 10/6          | 16/15         | 14/14         |
| Gender, males/females | 50/8     | 15/1          | 24/7          | 22/6          |
| Location: upper/middle/lower | 8/35/15 | 4/11/1        | 5/20/6        | 3/13/12       |
| Clinical stage:  |                  |               |               |               |
| cT1/cT2/cT3      | 53/15/0         | 12/3/1        | 10/13/8       | 7/7/14        |
| cN0/cN1/cN2      | 55/2/1          | 14/2/0        | 25/6/0        | 14/10/4       |
| cM0/cM1(LYM)     | 58/0            | 16/0          | 31/0          | 28/0          |
| cStage, I/II/III/IV | 55/2/1/0  | 13/3/0/0      | 20/7/4/0      | 9/9/10/0      |
| Pathological stage: |              |               |               |               |
| pT1/pT2/pT3/pT4  | 52/5/1/0        | 12/1/3/0      | 13/5/13/0     | 9/5/12/2      |
| pN0/pN1(LYM)     | 58/0            | 15/1          | 31/0          | 28/0          |
| pStage, I/II/III/IV | 57/1/0/0    | 0/13/3/0      | 18/13/0/0     | 0/14/12/2     |
| Recurrence, negative/positive | 54/4   | 14/2          | 21/10         | 15/13         |

| ESCC | Esophageal squamous cell carcinoma, TMTV | Total metabolic tumor volume, LYM | Supraclavicular lymph node metastasis |
|------|-----------------------------------------|----------------------------------|-------------------------------------|
| Total patients | 58 | 16 | 31 | 28 |
| Age, <66/≥66 | 27/31 | 10/6 | 16/15 | 14/14 |
| Gender, males/females | 50/8 | 15/1 | 24/7 | 22/6 |
| Location: upper/middle/lower | 8/35/15 | 4/11/1 | 5/20/6 | 3/13/12 |
| Clinical stage: | | | | |
| cT1/cT2/cT3 | 53/5/0 | 12/3/1 | 10/13/8 | 7/7/14 |
| cN0/cN1/cN2 | 55/2/1 | 14/2/0 | 25/6/0 | 14/10/4 |
| cM0/cM1(LYM) | 58/0 | 16/0 | 31/0 | 28/0 |
| cStage, I/II/III/IV | 55/2/1/0 | 13/3/0/0 | 20/7/4/0 | 9/9/10/0 |
| Pathological stage: | | | | |
| pT1/pT2/pT3/pT4 | 52/5/1/0 | 12/1/3/0 | 13/5/13/0 | 9/5/12/2 |
| pN0/pN1(LYM) | 58/0 | 15/1 | 31/0 | 28/0 |
| pStage, I/II/III/IV | 57/1/0/0 | 0/13/3/0 | 18/13/0/0 | 0/14/12/2 |
| Recurrence, negative/positive | 54/4 | 14/2 | 21/10 | 15/13 |
hematogenous metastasis rate and the rate of regional lymph node metastasis were both significantly lower in the patients with a TMTV < 3.82 compared to the patients with a TMTV ≥ 3.82, as follows. Hematogenous metastasis: TMTV < 3.82, 5.2% (4/76); TMTV ≥ 3.82, 28.7% (25/87), p < 0.001. Regional lymph node metastasis: TMTV < 3.82, 2.6% (2/76); TMTV ≥ 3.82, 13.8% (12/87), p = 0.011. No significant difference in local recurrence, dissemination, or distant lymph node metastases was observed between the low- and high-TMTV cut-off value groups.

**Discussion**

The relationship between the SUVmax and the prognosis of surgically resected esophageal cancer patients has been investigated. Kato et al. suggested that the peak SUVmax may be predictive of patients’ overall survival (OS); the 5-year OS rate for patients with a peak SUV ≥ 4.5 was 47% in their series, and the 5-year OS rate for those with a peak SUV < 4.5 was 76% [19]. However, Omloo et al. proposed that the SUVmax was not an independent prognostic factor for disease-free survival (DFS) [20]. The usefulness of the SUVmax for predicting the outcomes of resected esophageal cancer patients is thus controversial.

Investigations of MTV in esophageal cancer patients undergoing curative surgical resection alone have also been reported. A study by Hyun et al. showed that the MTV of the primary tumor was a better independent prognostic factor for OS than the SUVmax in 151 esophageal cancer patients [17]. Shum et al. suggested that the pretreatment MTV of the primary tumor was
a novel marker for the OS of 26 patients with ESCC treated with curative surgery [21].

There have been only a few investigations of the TMTV and wTLG for predicting the prognosis of ESCC patients who have undergone only a curative surgical resection. Park et al. reported that rather than the SUVmax and MTV, the wTLG was the only significant prognostic factor for both the DFS and OS of 50 ESCC patients [22]. In their study of 103 esophageal cancer patients, Foley et al. indicated that the TLG of the primary tumor, the metastatic length of disease, and the PET/CT total local nodal metastasis count were more important prognostic indicators for the patients’ survival than the TMTV [23]. Our present findings differ from these past reports. In most of the previous investigations, the correlation between the 18F-FDG uptake in the primary tumor and the prognosis of esophageal cancer patients was evaluated; the previous investigations included both ESCC patients and non-SCC patients; and the number of patients in the past investigations is lower than that of the present study.

Our study revealed that TMTV demonstrated consistently better performance than any other PET parameters in predicting recurrence until 72 months in a time-dependent ROC analysis, and the multivariate analysis revealed that TMTV was a more significant prognostic factor for RFS than other PET parameters in both models. The total recurrence and metastasis rates were both significantly higher in the patients with a TMTV ≥ 3.8; in particular, the occurrence rates of hematogenous metastasis and regional lymph node metastasis were significantly related to that TMTV value. Our results demonstrated that the TMTV was an independent prognostic factor for postoperative recurrence in resectable thoracic ESCC patients, and we thus propose that TMTV could be a useful preoperative risk factor for predicting postoperative recurrence in this patient population.

In our thoracic ESCC patient series, the N stage was a significant prognostic factor for predicting postoperative recurrence. The N stage has been classified according to the number of regional lymph node metastases instead of the location of lymph metastases since the 7th edition of TNM staging [13]. This N staging system is made based on survival with a significant difference between the survival curves of N0–N1 and N2–N3 [24]. Our data are agreement with this.

In the present study, the use of the TMTV enabled us to stratify the patients at high risk for recurrence among ESCC patients with cN0–1, pN0–1, and SA and SMR. Our analyses revealed that the patients with a TMTV < 3.8 cN0–1, TMTV < 3.8 pN0, TMTV < 3.8 pN1, and TMTV < 3.8 SA and SMR were at relatively low risk for recurrence. Conversely, the patients with a TMTV ≥ 3.8 cN0, TMTV ≥ 3.8 cN1, TMTV ≥ 3.8 pN0, TMTV ≥ 3.8 pN1, TMTV ≥ 3.8 SA and TMTV ≥ 3.8 SMR were at high risk for recurrence.

These data suggest that thoracic ESCC patients with a TMTV < 3.8 might be followed up without NAC or postoperative adjuvant therapy. Conversely, the patients with a TMTV ≥ 3.8 were at high risk for recurrence, and these patients may require postoperative adjuvant therapy or NAC. In addition, the TMTV ≥ 3.8 group included quite a few cStage I and pStage I thoracic ESCC patients. Thoracic ESCC patients with both TMTV ≥ 3.8 and stage I may need to undergo NAC or postoperative adjuvant chemotherapy.

The TMTV may thus be a crucial biomarker for stratifying thoracic ESCC patients at low and high risk for postoperative recurrence. To the best of our knowledge, the data that we obtained in this study have not been reported before, and we propose that the TMTV may be clinically useful for decisions about thoracic ESCC patient management.

The SULpeak was recently reported to be useful for predicting the tumor response and prognosis based on the PET Response Criteria in Solid Tumors (PERCIST) [25]. The SUL reduces dependence on the patients’ weight compared to the standard body weight-normalized SUV, and the SULpeak reduces the potential inconsistency of single-pixel measurements due to noise. The

| Pattern of failure                        | TMTV < 3.8 (pN0–3) (n = 76) | TMTV ≥ 3.8 (pN0–3) (n = 87) | p-value |
|------------------------------------------|-----------------------------|-----------------------------|---------|
| Local recurrence                         | 0 (0.0%)                    | 3 (3.4%)                    | 0.249   |
| Regional lymph node metastasis           | 2 (2.6%)                    | 12 (13.8%)                  | 0.011   |
| Hematogenous metastasis                  | 4 (5.2%)                    | 25 (28.7%)                  | <0.001  |
| Dissemination                            | 1 (1.3%)                    | 6 (6.9%)                    | 0.123   |
| Distant lymph node metastasis, M1(LYM)   | 0 (0.0%)                    | 5 (5.7%)                    | 0.061   |
| Total recurrence and metastasis          | 6 (7.9%)                    | 45 (51.7%)                  | <0.001  |

TMTV: Total metabolic tumor volume, LYM: Supraclavicular lymph node metastasis.
hsULpeak was not shown to be an independent prognostic factor for RFS following curative surgical resection in the present study, but the SULpeak has been reported to be useful for discriminating pathological responders and non-responders to NAC among ESCC patients [26]. The number of clinical investigations of SULpeak values in malignant tumor patients is less than that of other PET parameters, and the clinical usefulness of the SULpeak for malignant tumors remains under discussion.

This study has some limitations. It is retrospective study of thoracic ESCC patients surgically treated some time ago. Currently the eighth edition AJCC/UICC staging is used. However, we used the seventh edition AJCC/UICC staging in this study because the management of these thoracic ESCC patients was determined based on this edition. An investigation of $^{18}$F-FDG-PET/CT for predicting prognosis using the eighth edition of AJCC/UICC staging in thoracic ESCC patients should be conducted in a future study.

In addition, there is a possibility of patient selection bias. Thoracic ESCC patients who underwent NAC or NACRT were excluded from this study so that we could investigate the direct relationship between postoperative recurrence and PET parameters. Although NAC plus surgery is the currently recommended standard therapy for cStage II/III ESCC patients, surgery alone or surgery plus postoperative chemotherapy is performed for patients who are practically unable to ingest food due to stenosis or because of any factor that interferes with chemotherapy in the clinical setting [27]. In the present study, NAC was not administered to 63 patients with cStage II/III/IV due to several medical reasons, which led to heterogeneity of the patient population. We used $^{18}$F-FDG PET/CT to determine eligible patients for NAC for thoracic ESCC. Yasuda et al. investigated the usefulness of a lymph node evaluation by initial $^{18}$F-FDG PET in prediction of postoperative recurrence for resectable ESCC patients without induction therapy [8]. They suggested that resectable thoracic ESCC patients with PET-N-positive were likely to exhibit ≥3 pathological LNMs and a higher rate of postoperative distant recurrences, resulting in a much lower 5-year RFS compared with those with PET-N-negative (29.5 vs 75.1%, respectively) [8,28]. Aggressive NAC was done to thoracic ESCC patients with PET-N-positive to suppress postoperative recurrence, reducing the number of pathological LNMs, and improving 5-year RFS two-fold [12, 28]. In another investigation, they demonstrated that PET-N-negative status predicts ≥2 pathological LNMs and longer 5-year RFS compared with PET-N-positive in resectable thoracic ESCC patients after NAC (69.0 vs 20.0%) [28]. Thus, PET-N status is an important NAC treatment criterion for evaluating prognosis and deciding the patient management, and this criterion has been used before in clinical setting. PET-N-positive means candidate for NAC, and we carried out NAC followed by surgical resection for these patients. Alternatively, thoracic ESCC patients with PET-N-negative underwent curative surgical resection without NAC. The difference in background of cStage II-IV patients between patients who underwent NAC and those who did not mainly depend on PET-N status.

Although surgery is conducted under the diagnosis of cStage I, there may be cases in which the disease stage is found to be pStage II/III after surgical resection, and postoperative adjuvant chemotherapy is recommended in such cases [27]. Postoperative adjuvant chemotherapy with cisplatin and fluorouracil has been reported to be better able to prevent relapse in patients with esophageal cancer than surgery alone, but unfortunately there is no clear evidence that postoperative chemotherapy improves the OS of patients undergoing curative resection [27, 29]. If the optimal regimen for postoperative chemotherapy is clarified, TMTV may be a useful index for selecting the patients who should undergoing postoperative therapy.

We included the patients with a TMTV<3.8 cN1 or TMTV<3.8 SMR as TMTV<3.8 cN0–1 or TMTV<3.8 SA and SMR respectively. In this study, the number of patients with TMTV<3.8 cN1 and TMTV<3.8 SMR was low. These investigations for predicting prognosis should be done in a greater number of ESCC patients. A standard threshold for delineating $^{18}$F-FDG uptake for the MTV has not been established. Volumetric parameters are affected by the delineation method and threshold. The relative threshold could result in an overestimation of the MTV in a tumor with low metabolic activity, whereas a fixed value (e.g., SUV 2.5) could lead to underestimation [30]. We used volumetric parameters obtained from a threshold of 40% of the maximum peak activity because the threshold value of the SUVmax is the most commonly used in clinical settings. Our results should be confirmed by similar studies performed prospectively at different institutions.

Conclusions

The results of our analyses demonstrated that the TMTV was a more significant independent prognostic factor for RFS than any other PET parameters in resectable thoracic ESCC patients. The TMTV may be a more promising biomarker for the identification of patients at high risk for postoperative recurrence, and it could be useful for deciding the patient management in thoracic ESCC patients.
Abbreviations
ESCC: Esophageal squamous cell carcinoma; $^{18}$F-FDG-PET/CT: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; RFS: Relapse free survival; HR: Hazard ratio; CI: 95% confidential interval; LNMs: Lymph node metastases; NACRT: Neoadjuvant chemoradiotherapy; RFS: Relapse free survival; HR: Hazard ratio; 95% CI: 95% confidential interval; 18F-FDG-PET/CT: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography; RFS: Relapse free survival; HR: Hazard ratio; 95% CI: 95% confidential interval; ROC: Receiver operating characteristics curve; AUC: The area under the curve; SA: Surgical resection alone; SMR: Surgical resection without NAC due to several medical reasons; LYM: Supraclavicular lymph node metastasis.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10281-4.

Acknowledgements
Not applicable.

Authors’ contributions
Conception and design: H. Kaida, T. Yasuda. Acquiring data of ESCC patients: T. Yasuda, H. Kato, O. Shiraishi, Y. Kimura, M. Yamada, Y. Matsukubo. Analyzing and Interpreting PET data: H. Kaida, K. Kitajima, K. Ishii. Drafting the manuscript: H. Kaida, T. Yasuda, K. Hanaoka. Preparing Figs. 1-5 and 1S: H. Kaida, T. Yasuda, S. Hattori. Enhancing its intellectual content: T. Yasuda, K. Kitajima, K. Ishii, O. Shiraishi, S. Hattori. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study protocol was conducted according to the 1964 Declaration of Helsinki and the study was approved by the Ethics Committee, Kindai University Faculty of Medicine (approval no. 28–003). The Ethic Committee, Kindai University Faculty of Medicine waived the need for written informed consent due to the study’s retrospective design.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Radiology, Kindai University Faculty of Medicine, 377-2 Ohnohogashi, Osaka-Sayama, Osaka 589-8511, Japan. 2Division of Positron Emission Tomography, Institute of Advanced Clinical Medicine, Kindai University Hospital, Osaka-Sayama, Osaka 589-8511, Japan. 3Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka 589-8511, Japan. 4Department of Radiation, Division of Nuclear Medicine and PET Center, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan. 5Department of Biomedical Statistics, Osaka University Graduate School of Medicine, Suita, Japan. 6Institute for Open and Transdisciplinary Research Initiative, Osaka University, Suita, Osaka 565-0871, Japan.

Received: 20 February 2022 Accepted: 3 November 2022

Published online: 15 November 2022

References
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
2. Dresner SM, Griffin SM. Pattern of recurrence following radiological oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87(10):1426–33. https://doi.org/10.1046/j.1365-2168.2000.01541.x.
3. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. CROSS study group. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS). Long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):900–8. https://doi.org/10.1016/S1470-2045(15)00040-9.
4. Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19(1):68–74. https://doi.org/10.1245/s10434-011-12049-9.
5. Takahashi MES, Lorand-Metze I, de Souza CA, Mesquita CT, Fernandes FA, Carvalheira JBC, et al. Metabolic volume measurements in multiple myeloma. Metabolites. 2021;11(12):875. https://doi.org/10.3390/metabo11120875.
6. Makino T, Yamasaki M, Tanaka K, Masukeye T, Tatsumi M, Motoori M, et al. Metabolic tumor volume change predicts long-term survival and histological response to preoperative chemotherapy in locally advanced esophageal cancer. Ann Surg. 2019;270(6):1090–S. https://doi.org/10.1097/SLA.0000000000002808.
7. Chen SW, Hsieh TC, Ding HJ, Yen KY, Lin CY, Liang JA, et al. Pretreatment metabolic tumor volumes to predict the short-term outcome of unresectable locally advanced squamous cell carcinoma of the esophagus treated with definitive chemoradiotherapy. Nucl Med Commun. 2014;35(3):291–7. https://doi.org/10.1097/NM.0000000000000046.
8. Yasuda T, Higuchi I, Yano M, Miyata H, Yamasaki M, Takiguchi S, et al. The impact of $^{18}$F-fluorodeoxyglucose positron emission tomography positive lymph nodes on postoperative recurrence and survival in resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2012;19(2):652–60. https://doi.org/10.1245/s10434-011-1928-4.
9. Seban RD, Mezquita L, Berenbaum A, Derce L, Botticolla A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC Patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020;47(5):1147–57. https://doi.org/10.1007/s00259-019-04615-x.
10. Shagera QA, Cheon GJ, Koh Y, Yoo MY, Kang KW, Lee DS, et al. Prognostic value of metabolic tumour volume on baseline $^{18}$F-FDG PET/CT in addition to NCCN-PII in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-PII. Eur J Nucl Med Mol Imaging. 2019;46(7):1417–27. https://doi.org/10.1007/s00259-019-04309-4.
11. Takahashi N, Umezawa R, Takamani K, Yamamoto T, Ishikawa Y, Kozumi M, et al. Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2018;129(1):161–S. https://doi.org/10.1016/j.radonc.2017.10.019.
12. Yasuda T, Yano M, Miyata H, Yamasaki M, Higuchi I, Takiguchi S, et al. Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with $^{18}$F-fluorodeoxyglucose positron emission tomography-positive
lymph nodes. Surg Today. 2015;45(3):335–45. https://doi.org/10.1007/s00595-014-0956-7.

13. Sobin LH, Wittekind C. In (International Union against Cancer (UICC), eds: TNM classification of malignant tumors. 7th ed. Baltimore, MD: Wiley-Liss; 2000. p. 66–9.

14. Eskiian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F-FDG PET-scan: a systematic review and meta-analysis of 20,087 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46(1):224–37. https://doi.org/10.1007/s00259-018-4194-x.

15. Lemaignier C, Di Fiore F, Marie C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2008–16. https://doi.org/10.1007/s00259-014-2839-y.

16. Morgen DJ, Bray KM. Lean body mass as a predictor of drug dosage: implication for drug therapy. Clin Pharmacokinet. 1994;26(4):292–307. https://doi.org/10.2165/00003188-199426040-00005.

17. Hyun SH, Choi JY, Shim YM, Kim K, Lee SJ, Cho YS, et al. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol. 2010;17(1):115–22. https://doi.org/10.1245/s10434-009-0719-7.

18. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17(1):53. https://doi.org/10.1186/s12874-017-0332-6.

19. Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of (18) F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;15(14):3196–203. https://doi.org/10.1002/cncr.24399.

20. Omloo JM, Sloof GW, Boellaard R, Hoekstra OS, Jager PL, van Dullemen HM. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy. 2008;40(6):464–71. https://doi.org/10.1055/s-2008-1077302.

21. Shum WY, Ding HJ, Liang JA, Yen KY, Chen SW, Kao CH. Use of pretreatment metabolic tumor volumes on PET-CT to predict the survival of patients with squamous cell carcinoma of the esophagus treated by curative surgery. Anticancer Res. 2009;29(9):4163–8.

22. Park SY, Lee SJ, Yoon JK. The prognostic value of total lesion glycolysis via 18F-fluorodeoxyglucose PET-CT in surgically treated esophageal squamous cell carcinoma. Ann Nucl Med. 2016;30(1):81–8. https://doi.org/10.1007/s12149-015-1034-y.

23. Foley KG, Fielding P, Lewis WG, Karran A, Chan D, Blake P, et al. Prognostic significance of novel 18F-FDG PET/CT defined tumour variables in patients with oesophageal cancer. Eur J Radiol. 2014;83(7):1069–73. https://doi.org/10.1016/j.ejrad.2014.03.031.

24. Rice TW, Rusch WV, Ishwaran H, Blackstone EH. Worldwide esophageal Cancer collaboration. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American joint committee on Cancer/International Union against Cancer Cancer staging manuals. Cancer. 2010;116(16):3763–73. https://doi.org/10.1002/jco.21546.

25. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S. https://doi.org/10.2967/jnumed.108.057307.

26. Odawara S, Kitajima K, Katsuragi T, Kurahashi Y, Shinohara H, Yamakado K. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT — RECIST 1.1 vs. PERCIST 1.0. Eur J Radiol. 2018;101:65–71. https://doi.org/10.1016/j.ejrad.2018.02.009.

27. Kitajawa Y, Uno T, Oyama T, Kato K, Kato H, Kawakubo H, et al. Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 1. Esophagus. 2019;16(1):1–24. https://doi.org/10.1007/s10388-018-0641-9.

28. Yasuda T, Yano M, Miyata H, Yamasaki M, Takiguchi S, Fujiwara Y, et al. Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET)-positive lymph nodes following neoadjuvant chemotherapy and surgery for Resectable thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2015;22(8):2599–607. https://doi.org/10.1007/s10434-014-4299-9.